NCT02412111View on ClinicalTrials.gov

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

PHASE3CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

DRUG

Tezacaftor/Ivacaftor

Trial Locations (68)

Unknown

Birmingham

Oakland

San Diego

Aurora

Washington D.C.

Orlando

Augusta

Indianapolis

Lexington

Boston

Ann Arbor

Detroit

Grand Rapids

St Louis

Omaha

Lebanon

Manchester

Morristown

New Brunswick

Albany

New York

Cincinnati

Toledo

Oklahoma City

Portland

Philadelphia

Pittsburgh

Charleston

Knoxville

Nashville

Houston

Salt Lake City

Morgantown

Chermside

Clayton

Melbourne

South Brisbane

Westmead

Innsbruck

Brussels

Ghent

Leuven

Calgary

Toronto

Vancouver

Paris

Dresden

Erlangen

Essen

Frankfurt

Giessen

Heidelberg

Jena

München

Cork

Dublin

Bari

Milan

Roma

Belfast

Birmingham

Cardiff

Glasgow

Leeds

London

Manchester

Newcastle

Southampton

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02412111 - A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor | Biotech Hunter | Biotech Hunter